BMS looks forward to pivotal readouts for six assets in 2026, ensuring profits after patent expiries for Opdivo and Eliquis.

This effort, undertaken by Bristol Myers Squibb and agency partner Real Chemistry, is part of the Champions in Care campaign.

Harald Hampel is recognized as an influential leader in neuroscience, and will bring expertise in Alzheimer's disease to BMS.

The trial achieved its primary endpoint, showing a statistically significant reduction in Valsalva LVOT gradient at week 28.